Exp Mol Med.
2006 Jun;38(3):230-240.
Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells
- Affiliations
-
- 1Department of Endocrinology and Metabolism, The First Affiliated Hospital, China Medical University, Shenyang 110001, P.R. China. dzx_doctor@hotmail.com
- 2Department of Orthopedics, The First Municipal Hospital of Qinhuangdao, Qinhuangdao 066000, P.R. China.
- 3Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
- 4Department of Experimental Pathology, China Medical University, Shenyang 110001, P.R. China.
Abstract
-
Suvivin is a novel member of the inhibitor of apoptosis protein (IAP) family, which is known to be over-expressed in various carcinomas and associated with their biologically aggressive characteristics. The aim of this study was to investigate survivin expression in human medullary thyroid carcinoma (MTC) and a MTC cell line TT, correlate suvivin expression with clinicopathologic features of MTC, and test effects of antisurvivin oligonucleotides (ASODNs) on growth and apoptosis of TT cells. Survivin expression was immunohistochemically determined in formalin-fixed and paraffin-embedded specimens obtained from 10 cases of normal thyroid (NT) and 10 cases of MTC, and in TT cells. In TT cells, we confirmed survivin expression and its down-regulation by ASODNs using RT-PCR and Western blot analyses, and investigated effects of ASODNs on viability and growth by MTT assay and apoptosis by apoptotic analyses including DNA laddering assay, acridine orange/ethidium bromide staining and flow cytometric cell cycle analysis. Immunohistochemical analysis showed high survivin expression in MTC and TT cells, whereas no immunoreactivity was detectable in NT. Statistical analyses revealed no significant correlation of survivin expression with the clinicopathologic features of MTC. In TT cells, survivin expression at both mRNA and protein levels was confirmed and could be down-regulated by ASODNs concomitant with decrease in viability and growth, and increase in apoptosis. Our results suggest that survivin plays an important role in MTC independent of the conventional clinicopathologic factors, and ASODNs is a promising survivin-targeted gene therapy for MTC.